$SVRA
Savara Inc

2020 Q1 Form 10-K Financial Statement

#000156459020010465 Filed on March 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q4 2019 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.980M $3.300M $2.760M
YoY Change 7.97% 1.54% 55.93%
% of Gross Profit
Research & Development $13.20M $8.720M $1.400M
YoY Change 842.86% -11.56% -83.61%
% of Gross Profit
Depreciation & Amortization $242.0K $240.0K $307.0K
YoY Change -21.17% 71.43% 186.92%
% of Gross Profit
Operating Expenses $16.24M $12.08M $1.400M
YoY Change 1060.0% -8.83% -86.56%
Operating Profit -$31.51M -$12.92M
YoY Change 137.84% -59.76%
Interest Expense -$160.0K -$290.0K -$20.00K
YoY Change 700.0% -422.22% -80.77%
% of Operating Profit
Other Income/Expense, Net $820.0K $80.00K $960.0K
YoY Change -14.58% -42.86% -534.39%
Pretax Income -$15.42M -$31.72M -$12.11M
YoY Change 27.32% 143.63% -61.43%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$15.42M -$31.72M -$12.11M
YoY Change 27.32% 201.68% -54.89%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$268.8K -$723.2K -$336.2K
COMMON SHARES
Basic Shares Outstanding 50.84M 35.34M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q4 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $105.0M $121.8M $105.2M
YoY Change -0.19% 9.93% 23.76%
Cash & Equivalents $34.52M $49.80M $25.67M
Short-Term Investments $70.50M $72.00M $79.50M
Other Short-Term Assets $900.0K $700.0K $800.0K
YoY Change 12.5% -12.5% -50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $107.4M $124.1M $107.5M
YoY Change -0.05% 9.46% 22.72%
LONG-TERM ASSETS
Property, Plant & Equipment $294.0K $352.0K $1.700M
YoY Change -82.71% -32.57% 112.5%
Goodwill $0.00 $26.80M
YoY Change -100.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.306M $673.0K $1.100M
YoY Change 18.73% 413.74% 0.0%
Total Long-Term Assets $12.53M $12.14M $40.80M
YoY Change -69.29% -68.84% -1.21%
TOTAL ASSETS
Total Short-Term Assets $107.4M $124.1M $107.5M
Total Long-Term Assets $12.53M $12.14M $40.80M
Total Assets $120.0M $136.2M $148.3M
YoY Change -19.1% -10.56% 15.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.227M $3.409M $3.500M
YoY Change -64.94% -12.12% 2.94%
Accrued Expenses $6.502M $5.471M $5.100M
YoY Change 27.49% 62.1% 168.42%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $2.000M
YoY Change
Total Short-Term Liabilities $7.729M $10.88M $8.900M
YoY Change -13.16% 49.99% 64.81%
LONG-TERM LIABILITIES
Long-Term Debt $24.70M $23.10M $24.70M
YoY Change 0.0% -5.71% 62.5%
Other Long-Term Liabilities $199.0K $513.0K $12.90M
YoY Change -98.46% 632.86% 8.4%
Total Long-Term Liabilities $199.0K $513.0K $37.60M
YoY Change -99.47% 632.86% 38.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.729M $10.88M $8.900M
Total Long-Term Liabilities $199.0K $513.0K $37.60M
Total Liabilities $32.66M $34.51M $46.50M
YoY Change -29.77% -21.7% 32.1%
SHAREHOLDERS EQUITY
Retained Earnings -$207.9M
YoY Change 60.26%
Common Stock $309.6M
YoY Change 30.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $87.32M $101.7M $101.8M
YoY Change
Total Liabilities & Shareholders Equity $120.0M $136.2M $148.3M
YoY Change -19.08% -10.56% 15.05%

Cashflow Statement

Concept 2020 Q1 2019 Q4 2019 Q1
OPERATING ACTIVITIES
Net Income -$15.42M -$31.72M -$12.11M
YoY Change 27.32% 201.68% -54.89%
Depreciation, Depletion And Amortization $242.0K $240.0K $307.0K
YoY Change -21.17% 71.43% 186.92%
Cash From Operating Activities -$13.08M -$9.940M -$10.86M
YoY Change 20.44% -5.33% 12.28%
INVESTING ACTIVITIES
Capital Expenditures $4.000K -$10.00K $96.00K
YoY Change -95.83% -83.33% 405.26%
Acquisitions
YoY Change
Other Investing Activities $1.470M $16.76M $7.420M
YoY Change -80.19% 1702.15% -21.15%
Cash From Investing Activities -$1.785M $16.75M $7.320M
YoY Change -124.39% 1825.29% -22.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.890M
YoY Change 891.89%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -466.0K 25.25M 4.896M
YoY Change -109.52% 177.78% 1706.64%
NET CHANGE
Cash From Operating Activities -13.08M -9.940M -10.86M
Cash From Investing Activities -1.785M 16.75M 7.320M
Cash From Financing Activities -466.0K 25.25M 4.896M
Net Change In Cash -15.29M 32.06M 1.370M
YoY Change -1215.99% -6037.04% 136900.0%
FREE CASH FLOW
Cash From Operating Activities -$13.08M -$9.940M -$10.86M
Capital Expenditures $4.000K -$10.00K $96.00K
Free Cash Flow -$13.08M -$9.930M -$10.96M
YoY Change 19.42% -4.89% 13.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Liabilities
Liabilities
44068000
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
50838879
CY2019Q2 dei Entity Public Float
EntityPublicFloat
77999482
CY2018Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
12214000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
70000
CY2018Q4 us-gaap Goodwill
Goodwill
26918000
CY2019 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2019 dei Trading Symbol
TradingSymbol
SVRA
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49804000
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
71957000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2306000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
52000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
124067000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
352000
CY2019Q4 svra In Process Research And Development
InProcessResearchAndDevelopment
11111000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50790441
CY2018 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
21692000
CY2019 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
26852000
CY2019 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
38781000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10654000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13081000
CY2018Q4 us-gaap Assets
Assets
152287000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3879000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3375000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10880000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7254000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
513000
CY2019Q4 us-gaap Liabilities
Liabilities
34505000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
36000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
237702000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
131000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
200000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-129719000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
108219000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
152287000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35146096
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35146096
CY2018 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
37173000
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
673000
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity File Number
EntityFileNumber
001-32157
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1318182
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
6836 Bee Cave Road
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
Building III
CY2019 dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 200
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78746
CY2019 dei City Area Code
CityAreaCode
512
CY2019 dei Local Phone Number
LocalPhoneNumber
614-1848
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24301000
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
86529000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2514000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
113344000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
522000
CY2018Q4 svra In Process Research And Development
InProcessResearchAndDevelopment
11372000
CY2019Q4 us-gaap Assets
Assets
136203000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3409000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5471000
CY2019Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
2000000
CY2019Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
23112000
CY2018Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
24530000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018 svra Change In Fair Value Of Financial Instruments Net Of Contingent Consideration
ChangeInFairValueOfFinancialInstrumentsNetOfContingentConsideration
-64000
CY2019 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-78000
CY2018 svra Issuance Of Common Stock Upon Exercise Of Warrants Amount
IssuanceOfCommonStockUponExerciseOfWarrantsAmount
19000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4441000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50790441
CY2018 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
11000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
309555000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-17000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-207892000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
101698000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
136203000
CY2018 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
71000
CY2018 svra Tax Credit Income
TaxCreditIncome
1454000
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40027758
CY2019 us-gaap Depreciation
Depreciation
311000
CY2018 us-gaap Depreciation
Depreciation
526000
CY2019 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-70000
CY2019 svra Tax Credit Income
TaxCreditIncome
1213000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-78173000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7057000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-78173000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-61516000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.95
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.85
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33300704
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-296000
CY2018 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-773000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
79000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
15000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-78390000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-62274000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
119309000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
45792000
CY2018 svra Issuance Of Common Stock Upon At The Market Offering Net
IssuanceOfCommonStockUponAtTheMarketOfferingNet
505000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
58000
CY2018 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
995000
CY2018 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
78000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3737000
CY2019 svra Issuance Of Securities In Private Placement Net Closing Costs
IssuanceOfSecuritiesInPrivatePlacementNetClosingCosts
25247000
CY2019 svra Issuance Of Common Stock Upon At The Market Sales Net
IssuanceOfCommonStockUponAtTheMarketSalesNet
29592000
CY2019 svra Issuance Of Common Stock Upon Settlement Of Contingent Liability
IssuanceOfCommonStockUponSettlementOfContingentLiability
12478000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
111000
CY2019 us-gaap Profit Loss
ProfitLoss
-78173000
CY2018 us-gaap Profit Loss
ProfitLoss
-61516000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1010000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
526000
CY2019 svra Change In Fair Value Of Financial Instruments
ChangeInFairValueOfFinancialInstruments
-213000
CY2018 svra Change In Fair Value Of Financial Instruments
ChangeInFairValueOfFinancialInstruments
-64000
CY2019 svra Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
264000
CY2018 svra Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
266000
CY2019 svra Paid In Kind Interest Income Expense
PaidInKindInterestIncomeExpense
-72000
CY2018 svra Paid In Kind Interest Income Expense
PaidInKindInterestIncomeExpense
75000
CY2018 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
995000
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
582000
CY2018 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
468000
CY2019 svra Accretion On Discount To Short Term Investments
AccretionOnDiscountToShortTermInvestments
1161000
CY2018 svra Accretion On Discount To Short Term Investments
AccretionOnDiscountToShortTermInvestments
900000
CY2019 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
4000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
4441000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
3737000
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-7057000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-148000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-900000
CY2019 svra Increase Decrease In Noncurrent Assets
IncreaseDecreaseInNoncurrentAssets
-131000
CY2019 svra Increase Decrease In Accounts Payable And Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
568000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22121000
CY2018 svra Increase Decrease In Accounts Payable And Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
1546000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45123000
CY2018 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
9365000
CY2018 svra Proceeds From Issuance Of Common Stock Upon Exercise Of Warrants
ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants
19000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
1406000
CY2018 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
45792000
CY2019 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
25247000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
110000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
58000
CY2019 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
41000
CY2018 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
546000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
54908000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55193000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-22000
CY2018 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-119000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
25503000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2180000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24301000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
49804000
CY2018 svra Common Stock Issued For In Process Research And Development Net
CommonStockIssuedForInProcessResearchAndDevelopmentNet
995000
CY2019 svra Non Cash Settlement Of Contingent Consideration
NonCashSettlementOfContingentConsideration
12478000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
2099000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39275000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
148000
CY2019 svra Payments For Proceeds From Available For Sale Securities Debt
PaymentsForProceedsFromAvailableForSaleSecuritiesDebt
122945000
CY2018 svra Payments For Proceeds From Available For Sale Securities Debt
PaymentsForProceedsFromAvailableForSaleSecuritiesDebt
122494000
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
124700000
CY2018 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
98746000
CY2019 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
14133000
CY2018 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
10270000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15740000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13619000
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Use of Estimates </font></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Management&#8217;s estimates include those related to the accrual of research and development costs, control premiums used in goodwill and IPR&amp;D reviews, certain financial instruments recorded at fair value, stock-based compensation, contingent consideration prior to its settlement during the year ended December 31, 2019, and the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Accordingly, actual results could be materially different from those estimates. </font></p>
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Concentration of Credit Risk </font></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents and foreign exchange derivatives not designated as hedging. The Company places its cash and cash equivalents with a limited number of financial institutions and at times may exceed the amount of insurance provided on such deposits. </font></p>
CY2019Q4 svra Accrued Lease Liability
AccruedLeaseLiability
440000
CY2018Q4 svra Accrued Current Portion Of Capital Lease Obligation
AccruedCurrentPortionOfCapitalLeaseObligation
41000
CY2019Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
71909000
CY2018Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
86559000
CY2019 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2019 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2019 svra Liquid Investments Maturity Period
LiquidInvestmentsMaturityPeriod
three months or less
CY2019 svra In Process Research And Development Decrease
InProcessResearchAndDevelopmentDecrease
300000
CY2019Q4 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
19400000
CY2019Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
7400000
CY2019Q4 us-gaap Goodwill Fair Value Disclosure
GoodwillFairValueDisclosure
0
CY2019 svra Date Of Agreement
DateOfAgreement
2018-10-08
CY2019 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
11334000
CY2019Q4 svra Contingent Milestones Or Co Marketing Commitments Incurred
ContingentMilestonesOrCoMarketingCommitmentsIncurred
0
CY2019Q4 svra Contingent Milestones Or Co Marketing Commitments Remunerated
ContingentMilestonesOrCoMarketingCommitmentsRemunerated
0
CY2019Q4 svra Contingent Milestones Or Co Marketing Commitments Accrued
ContingentMilestonesOrCoMarketingCommitmentsAccrued
0
CY2019Q4 svra Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
1253000
CY2018Q4 svra Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
1263000
CY2019Q4 svra Prepaid Contracted Research And Development Costs
PrepaidContractedResearchAndDevelopmentCosts
184000
CY2018Q4 svra Prepaid Contracted Research And Development Costs
PrepaidContractedResearchAndDevelopmentCosts
561000
CY2019Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
364000
CY2018Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
421000
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
247000
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
162000
CY2019Q4 svra Foreign Currency Exchange Derivative Current
ForeignCurrencyExchangeDerivativeCurrent
7000
CY2019Q4 svra Deposits And Other Assets Current
DepositsAndOtherAssetsCurrent
251000
CY2018Q4 svra Deposits And Other Assets Current
DepositsAndOtherAssetsCurrent
107000
CY2019Q4 svra Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
2018000
CY2018Q4 svra Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
2044000
CY2019Q4 svra Accrued General And Administrative Costs
AccruedGeneralAndAdministrativeCosts
1710000
CY2018Q4 svra Accrued General And Administrative Costs
AccruedGeneralAndAdministrativeCosts
371000
CY2019Q4 svra Accrued Compensation
AccruedCompensation
1303000
CY2018Q4 svra Accrued Compensation
AccruedCompensation
643000
CY2018Q4 svra Forward Currency Exchange Derivative
ForwardCurrencyExchangeDerivative
26000
CY2018Q4 us-gaap Deferred Revenue
DeferredRevenue
250000
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2019Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
51000
CY2019Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2018Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
30000
CY2019Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
71957000
CY2018Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
86529000
CY2019 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2018 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2026000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1890000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1674000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1368000
CY2017Q2 svra Debt Instrument Prepayment Fee Percentage
DebtInstrumentPrepaymentFeePercentage
0.060
CY2019 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
400000
CY2019Q4 svra Principal Payments Of Debt And End Of Term Charge Current
PrincipalPaymentsOfDebtAndEndOfTermChargeCurrent
2000000
CY2019Q4 svra Principal Payments Of Debt And End Of Term Charge Non Current
PrincipalPaymentsOfDebtAndEndOfTermChargeNonCurrent
23452000
CY2019Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
182000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
158000
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2000000
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
12000000
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
12500000
CY2019Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
26500000
CY2019Q4 svra Unamortized End Of Term Charge
UnamortizedEndOfTermCharge
1048000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
340000
CY2019Q4 us-gaap Line Of Credit
LineOfCredit
25112000
CY2019Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2018Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2019Q4 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
25247000
CY2019Q4 svra Common Stock And Preferred Stock Shares Authorized
CommonStockAndPreferredStockSharesAuthorized
201000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
44544392
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4910016
CY2019Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
39687335
CY2017Q4 svra Lease Commencement Date
LeaseCommencementDate
2018-01-01
CY2017Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-07-31
CY2017Q4 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
200000
CY2019 svra Lease Commencement Date
LeaseCommencementDate
2018-11-01
CY2019 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-09-30
CY2019 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
100000
CY2019Q4 svra Lease Rental Payments Percentage
LeaseRentalPaymentsPercentage
0.02
CY2017Q1 svra Operating Lease Office Space
OperatingLeaseOfficeSpace
13707
CY2017Q1 svra Lease Commencement Date
LeaseCommencementDate
2017-07-01
CY2017Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-05-31
CY2017Q1 svra Lease Agreement Date
LeaseAgreementDate
2014-06-19
CY2019 us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
500000
us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
100000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
478000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
184000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
67000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
786000
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P18Y8M12D
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.085
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
700000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
400000
CY2019Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
300000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Impairment Losses
IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
5671000
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
854000
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
1043000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
12800000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8700000
CY2019 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-312000
CY2018 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-305000
CY2019 svra Employment Agreement Description
EmploymentAgreementDescription
Upon termination without cause, and not as a result of death or disability, or resignation for good reason, each of such officers is entitled to receive a payment of base salary for twelve months and a pro-rated portion of their unpaid bonus following termination of employment, and such officer will be entitled to continue to receive coverage under medical and dental benefit plans for twelve months or until such officer is covered under a separate plan from another employer. Upon a termination other than for cause or resignation for good reason within twelve months following a change in control, each of such officers is entitled to receive a payment of base salary for eighteen months and one-hundred percent of their unpaid bonus following termination of employment and such officer will be entitled to continue to receive coverage under medical and dental benefit plans for twelve months or until such officer is covered under a separate plan from another employer and will also be entitled to certain acceleration of such officer’s outstanding nonvested options at the time of such termination.
CY2019 svra Percentage Of Unpaid Bonus To Be Paid Upon Termination
PercentageOfUnpaidBonusToBePaidUponTermination
1.00
CY2019 svra Purchase Price Of Common Stock Covered By Stock Option As Percentage Of Fair Market Value Of Common Stock
PurchasePriceOfCommonStockCoveredByStockOptionAsPercentageOfFairMarketValueOfCommonStock
Less than 100%
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1.00
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4541432
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1901039
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4441000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3737000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-52440000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-48868000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-25733000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-19705000
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-4555000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2018 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
124000
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
124000
CY2018 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-2626000
CY2018 svra Deferred Federal Foreign Income Tax Expense Benefit
DeferredFederalForeignIncomeTaxExpenseBenefit
-7181000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-16416000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-14706000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
12780000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
8692000
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
2855000
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
2945000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
278000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
1164000
CY2019Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
2143000
CY2018Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
2845000
CY2019Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
516000
CY2018Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
251000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2659000
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3096000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
30953000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
21406000
CY2019Q4 svra Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
97000
CY2018Q4 svra Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
208000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
15654000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
12706000
CY2019Q4 svra Deferred Tax Assets Accrued Liabilities And Other
DeferredTaxAssetsAccruedLiabilitiesAndOther
365000
CY2018Q4 svra Deferred Tax Assets Accrued Liabilities And Other
DeferredTaxAssetsAccruedLiabilitiesAndOther
318000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
47069000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
34638000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
44410000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
31542000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
44410000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
31542000
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
40300000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
23100000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
1800000
CY2018Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2500000
CY2019Q4 svra Percentage Increase In Shareholders Ownership Interest
PercentageIncreaseInShareholdersOwnershipInterest
0.05
CY2019Q4 svra Minimum Percentage Points Change In Ownership Interest
MinimumPercentagePointsChangeInOwnershipInterest
0.0050
CY2019 svra Change In Ownership Interest Period
ChangeInOwnershipInterestPeriod
P3Y
CY2019Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2018Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2019 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2018 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37988855
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4135016
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-78173000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-61516000
CY2019 svra Undistributed Earnings And Net Income Loss Attributable To Common Stockholders Basic And Diluted
UndistributedEarningsAndNetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-78173000
CY2018 svra Undistributed Earnings And Net Income Loss Attributable To Common Stockholders Basic And Diluted
UndistributedEarningsAndNetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-61516000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12920000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22154000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12442000
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-31509000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-12112000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-21939000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-12403000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-31719000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.57
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-32107000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11906000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12784000
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-13248000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-26849000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-11593000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-12560000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-10514000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.86
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2018Q1 svra Increase Decrease Earnings Per Share Basic And Diluted
IncreaseDecreaseEarningsPerShareBasicAndDiluted
-0.02
CY2018Q2 svra Increase Decrease Earnings Per Share Basic And Diluted
IncreaseDecreaseEarningsPerShareBasicAndDiluted
-0.01
CY2018Q3 svra Increase Decrease Earnings Per Share Basic And Diluted
IncreaseDecreaseEarningsPerShareBasicAndDiluted
-0.01

Files In Submission

Name View Source Status
0001564590-20-010465-index-headers.html Edgar Link pending
0001564590-20-010465-index.html Edgar Link pending
0001564590-20-010465.txt Edgar Link pending
0001564590-20-010465-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gfe3tqbi1yqb000001.jpg Edgar Link pending
gtdtjos4z4i5000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
svra-10k_20191231.htm Edgar Link pending
svra-20191231.xml Edgar Link completed
svra-20191231.xsd Edgar Link pending
svra-20191231_cal.xml Edgar Link unprocessable
svra-20191231_def.xml Edgar Link unprocessable
svra-20191231_lab.xml Edgar Link unprocessable
svra-20191231_pre.xml Edgar Link unprocessable
svra-ex1036_15.htm Edgar Link pending
svra-ex1037_16.htm Edgar Link pending
svra-ex1039_618.htm Edgar Link pending
svra-ex231_11.htm Edgar Link pending
svra-ex232_474.htm Edgar Link pending
svra-ex311_7.htm Edgar Link pending
svra-ex312_9.htm Edgar Link pending
svra-ex321_6.htm Edgar Link pending
svra-ex425_1036.htm Edgar Link pending